Clinical Trials Logo

Clinical Trial Summary

Pre-clinical in vitro and in vivo data as well as early phase 1 clinical trials have shown that both hematologic and solid tumor cells are susceptible to single-agent cytotoxicity by CPI-613 (devimistat), consistent with its selective target of the altered form of mitochondrial energy metabolism in tumor cells, causing changes in mitochondrial enzyme activities and redox status, which lead to apoptosis, necrosis, and autophagy of tumor cells leading to the death of cancer cells. It is our hypothesis that CPI-613 (devimistat) will enhance the efficacy of mFOLFIRINOX plus Bevacizumab when given as a combination treatment. The study will follow a standard 3+3 design. Cohorts of three to six patients will be treated at each dose level until the MTD is defined.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05070104
Study type Interventional
Source Rafael Pharmaceuticals Inc.
Contact Sanjeev Luther
Phone 5859781351
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date January 30, 2022
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT00212615 - XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer Phase 2/Phase 3